CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 2.33 and has seen 1,434,022 shares traded in the recent trading session. The company, currently valued at $4.91 Billion, closed the recent trade at $78.21 per share which meant it gained $5.7 on the day or 7.84% during that session. The CRSP stock price is -2.19% off its 52-week high price of $79.92 and 58.7% above the 52-week low of $32.3. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.36 Million shares traded. The 3-month trading volume is 961.39 Million shares.
Sporting 6.42% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the CRSP stock price touched $77.87- or saw a rise of 0.9%. Year-to-date, CRISPR Therapeutics AG shares have moved 26.71%, while the 5-day performance has seen it change 5.58%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed 15.89%. Short interest in the company has seen 3.84 Million shares shorted with days to cover at 0.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Figures show that CRISPR Therapeutics AG shares have underperformed across the wider relevant industry. The company’s shares have gained +18.84% over the past 6 months, with this year growth rate of -490.6%, compared to 9.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 5% and -150.8% for the next quarter. Revenue growth from the last financial year stood is estimated to be -94.2%.
11 analysts offering their estimates for the company have set an average revenue estimate of $17.5 Million for the current quarter. 11 have an estimated revenue figure of $2.1 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $3.94 Million for this quarter, and analysts expect sales will grow by 344.2% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +54% over the past 5 years. Earnings growth for 2020 is a modest +134.1% while over the next 5 years, the company’s earnings are expected to increase by 0%.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders own 20.94% of the company shares, while shares held by institutions stand at 55.73% with a share float percentage of 70.5%. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 350 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 4.29 Million shares worth more than $181.75 Million. As of March 30, 2020, ARK Investment Management, LLC held 7.02% of shares outstanding.
The other major institutional holder is Versant Venture Management, LLC, with the holding of over 4.21 Million shares as of March 30, 2020. The firm’s total holdings are worth over $178.36 Million and represent 6.89% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. As of April 29, 2020, the former fund manager holds about 4.21% shares in the company for having 2566352 shares of worth $126.26 Million while later fund manager owns 1.26 Million shares of worth $62.12 Million as of April 29, 2020, which makes it owner of about 2.07% of company’s outstanding stock.